Bibliography for MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies BETA

Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA, 298(2). https://doi.org/10.1001/jama.298.2.194

Amy Kennedy. (2013). Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE, 8(3). https://doi.org/doi:  10.1371/journal.pone.0058861

Anderson, B., Funnell, M., & American Diabetes Association. (2005). The art of empowerment: stories and strategies for diabetes educators (2nd ed). American Diabetes Association.

Anthony H. Barnett, Jenny Grice. (2013). New Mechanisms in Glucose Control. BMJ Books; 1 edition. http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133

[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics. (n.d.). http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200

Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006). Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine, 23(3), 285–292. https://doi.org/10.1111/j.1464-5491.2005.01781.x

Atkinson, M. A. (2012). The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine, 2(11), a007641–a007641. https://doi.org/10.1101/cshperspect.a007641

Avery, L., Flynn, D., van Wersch, A., Sniehotta, F. F., & Trenell, M. I. (2012). Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care, 35(12), 2681–2689. https://doi.org/10.2337/dc11-2452

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet, 375(9733), 2223–2233. https://doi.org/10.1016/S0140-6736(10)60407-2

Barry, V. W., Baruth, M., Beets, M. W., Durstine, J. L., Liu, J., & Blair, S. N. (2014). Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases, 56(4), 382–390. https://doi.org/10.1016/j.pcad.2013.09.002

Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., Nicholson, W. K., Hutfless, S., Bass, E. B., & Bolen, S. (2011). Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine, 154(9). https://doi.org/10.7326/0003-4819-154-9-201105030-00336

Bethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., Peterson, E. D., & Holman, R. R. (2017). Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Diabetes Care. https://doi.org/10.2337/dc16-1135

Beverley M Shields. (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 5(11). https://doi.org/doi:  10.1136/bmjopen-2015-009088

Birkeland, K. I. (2015). Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology, 3(10), 752–753. https://doi.org/10.1016/S2213-8587(15)00282-X

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008). Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet, 371(9618), 1073–1084. https://doi.org/10.1016/S0140-6736(08)60485-7

Brown, J., Alwan, N. A., West, J., Brown, S., McKinlay, C. J., Farrar, D., & Crowther, C. A. (1996). Lifestyle interventions for the treatment of women with gestational diabetes. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD011970.pub2

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine, 154(2). https://doi.org/10.7326/0003-4819-154-2-201101180-00300

Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., & Porter, L. E. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care, 33(6), 1255–1261. https://doi.org/10.2337/dc09-1914

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet, 374(9683), 39–47. https://doi.org/10.1016/S0140-6736(09)60659-0

Capehorn, M., Polonsky, W. H., Edelman, S., Belton, A., Down, S., Gamerman, V., Nagel, F., Lee, J., & Alzaid, A. (2017). Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia                              ). Diabetic Medicine. https://doi.org/10.1111/dme.13357

Carver, C. (2006). Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. The Diabetes Educator, 32(6), 910–917. https://doi.org/10.1177/0145721706294259

Celia G. Walker. (2015). Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. PLoS ONE, 10(7). https://doi.org/doi:  10.1371/journal.pone.0131681

Chatterjee, S., & Davies, M. (2015). Type 2 diabetes: recent advances in diagnosis and management. Prescriber, 26(10), 15–21. https://doi.org/10.1002/psb.1355

Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012). What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia, 55(3), 542–551. https://doi.org/10.1007/s00125-011-2403-2

Choudhary, P., Parrott, N. R., Birtles, L., & Rutter, M. K. (2012). Islet cell transplantation: current status in the UK (2012). Practical Diabetes, 29(7), 280–285. https://doi.org/10.1002/pdi.1707

Copeland, K. C., Silverstein, J., Moore, K. R., Prazar, G. E., Raymer, T., Shiffman, R. N., Springer, S. C., Thaker, V. V., Anderson, M., Spann, S. J., & Flinn, S. K. (2013). Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS, 131(2), 364–382. https://doi.org/10.1542/peds.2012-3494

Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017). Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, 79–87. https://doi.org/10.2147/DMSO.S126763

Crasto, W., Jarvis, J., & Davies, M. J. (2016a). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Crasto, W., Jarvis, J., & Davies, M. J. (2016b). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Crasto, W., Jarvis, J., & Davies, M. J. (2016c). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Crasto, W., Jarvis, J., & Davies, M. J. (2016d). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Crasto, W., Jarvis, J., & Davies, M. J. (2016e). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Crasto, W., Jarvis, J., & Davies, M. J. (2016f). Handbook of insulin therapies. Adis. http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., & Jarvis, J. (2015). Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes, 32(8), 305–310a. https://doi.org/10.1002/pdi.1979

Davies, M., Dahl, D., Heise, T., Kiljanski, J., & Mathieu, C. (2017). Introduction of biosimilar insulins in Europe. Diabetic Medicine, 34(10), 1340–1353. https://doi.org/10.1111/dme.13400

Davies, M. J., & Chatterjee, S. (2017). Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology, 13(6), 317–318. https://doi.org/10.1038/nrendo.2017.41

Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Cradock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., Fox, C., Oliver, L., Rantell, K., Rayman, G., & Khunti, K. (2008). Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ, 336(7642), 491–495. https://doi.org/10.1136/bmj.39474.922025.BE

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., & Gomis, R. (2005). Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care, 28(6), 1282–1288. https://doi.org/10.2337/diacare.28.6.1282

Deacon, C. F., & Lebovitz, H. E. (2016). Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism, 18(4), 333–347. https://doi.org/10.1111/dom.12610

Dhatariya, K. K., Skedgel, C., & Fordham, R. (2017). The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine, 34(10), 1361–1366. https://doi.org/10.1111/dme.13427

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010a). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet, 375(9733), 2234–2243. https://doi.org/10.1016/S0140-6736(10)60406-0

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010b). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet, 375(9733), 2234–2243. https://doi.org/10.1016/S0140-6736(10)60406-0

Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet, 384(9951), 1349–1357. https://doi.org/10.1016/S0140-6736(14)60976-4

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials- ClinicalKey. (n.d.). https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016). New England Journal of Medicine, 375(18), 1799–1802. https://doi.org/10.1056/NEJMc1611290

Evans, M., Schumm-Draeger, P. M., Vora, J., & King, A. B. (2011). A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism, 13(8), 677–684. https://doi.org/10.1111/j.1463-1326.2011.01395.x

Frandsen, C. S. S., & Madsbad, S. (2014). Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine, 31(11), 1293–1300. https://doi.org/10.1111/dme.12561

Funnell, M. M. (2007). Overcoming Barriers to the Initiation of Insulin Therapy. Clinical Diabetes, 25(1), 36–38. https://doi.org/10.2337/diaclin.25.1.36

Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012). 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet, 380(9840), 475–483. https://doi.org/10.1016/S0140-6736(12)60691-6

Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet, 379(9825), 1498–1507. https://doi.org/10.1016/S0140-6736(12)60205-0

Garber, A. J., Ligthelm, R., Christiansen, J. S., & Liebl, A. (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism, 9(5), 630–639. https://doi.org/10.1111/j.1463-1326.2006.00654.x

Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism, 8(1), 58–66. https://doi.org/10.1111/j.1463-1326.2005.00563.x

Gough, S. C. L. (2007). A review of human and analogue insulin trials. Diabetes Research and Clinical Practice, 77(1), 1–15. https://doi.org/10.1016/j.diabres.2006.10.015

Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013). Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes, Obesity and Metabolism, 15(4), 301–309. https://doi.org/10.1111/dom.12052

Grammes, J., Stock, W., Mann, C. G., Flynn, E. M., & Kubiak, T. (2017). Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine. https://doi.org/10.1111/dme.13506

Gray, L. J., Khunti, K., Edwardson, C., Goldby, S., Henson, J., Morris, D. H., Sheppard, D., Webb, D., Williams, S., Yates, T., & Davies, M. J. (2012). Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia, 55(12), 3238–3244. https://doi.org/10.1007/s00125-012-2725-8

Gray, L. J., Khunti, K., Wilmot, E. G., Yates, T., & Davies, M. J. (2014). External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice, 104(3), 451–458. https://doi.org/10.1016/j.diabres.2014.03.018

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 373(3), 232–242. https://doi.org/10.1056/NEJMoa1501352

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016a). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 92(1085), 152–164. https://doi.org/10.1136/postgradmedj-2015-133716

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016b). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 92(1085), 152–164. https://doi.org/10.1136/postgradmedj-2015-133716

Hadjiconstantinou, M., Byrne, J., Bodicoat, D. H., Robertson, N., Eborall, H., Khunti, K., & Davies, M. J. (2016). Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 18(10). https://doi.org/10.2196/jmir.5991

Hartman, Y. A. W., Jansen, H. J., Hopman, M. T. E., Tack, C. J., & Thijssen, D. H. J. (2017). Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care, 40(9), e120–e121. https://doi.org/10.2337/dc17-0787

Heinonen, I., Helajärvi, H., Pahkala, K., Heinonen, O. J., Hirvensalo, M., Pälve, K., Tammelin, T., Yang, X., Juonala, M., Mikkilä, V., Kähönen, M., Lehtimäki, T., Viikari, J., & Raitakari, O. T. (2013). Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open, 3(6). https://doi.org/10.1136/bmjopen-2013-002901

Heller, S. R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B. H. R., Koelendorf, K., Friberg, H. H., Windfeld, K., & Lindholm, A. (2004). Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine, 21(7), 769–775. https://doi.org/10.1111/j.1464-5491.2004.01244.x

Henson, Joseph. (2014). Associations of Sedentary Time with Fat Distribution in a High-Risk Population. https://lra.le.ac.uk/handle/2381/32505

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, 29(6), 1269–1274. https://doi.org/10.2337/dc05-1365

Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007). Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 357(17), 1716–1730. https://doi.org/10.1056/NEJMoa075392

Holman, R. R., & Turner, R. C. (1985). A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine, 2(1), 45–53. https://doi.org/10.1111/j.1464-5491.1985.tb00592.x

Home, P. D. (2012). The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism, 14(9), 780–788. https://doi.org/10.1111/j.1463-1326.2012.01580.x

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996a). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD005613.pub3

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996b). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD005613.pub3

Htike, Z. Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. J. (2016). Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. British Journal of Diabetes, 16(3). https://doi.org/10.15277/bjd.2016.091

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017a). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism, 19(4), 524–536. https://doi.org/10.1111/dom.12849

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017b). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism, 19(4), 524–536. https://doi.org/10.1111/dom.12849

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441

Ismail-Beigi, F. (2012). Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine, 366(14), 1319–1327. https://doi.org/10.1056/NEJMcp1013127

John M Jakicic. (2005). Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition, 82(1), 226S-229S. http://ajcn.nutrition.org/content/82/1/226S

Johnston, B. C., Kanters, S., Bandayrel, K., Wu, P., Naji, F., Siemieniuk, R. A., Ball, G. D. C., Busse, J. W., Thorlund, K., Guyatt, G., Jansen, J. P., & Mills, E. J. (2014). Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA, 312(9). https://doi.org/10.1001/jama.2014.10397

Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803–817. https://doi.org/10.1111/dme.12159

Kamlesh Khunti. (2015). Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE, 10(9). https://doi.org/doi:  10.1371/journal.pone.0135702

Kenneth Hodson. (2010). Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine, 3(4). https://doi.org/doi:  10.1258/om.2010.100025

Latika Sahu. (2009). Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine, 2(4). https://doi.org/doi:  10.1258/om.2009.080049

Lee, I.-M. (2010). Physical Activity and Weight Gain Prevention. JAMA, 303(12). https://doi.org/10.1001/jama.2010.312

Leff, D. R., & Heath, D. (2009). Surgery for obesity in adulthood. BMJ, 339(sep22 1), b3402–b3402. https://doi.org/10.1136/bmj.b3402

Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 10, 123–139. https://doi.org/10.2147/DMSO.S130834

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016). New England Journal of Medicine, 375(18), 1797–1799. https://doi.org/10.1056/NEJMc1611289

Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999). Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia, 42(4), 406–412. https://doi.org/10.1007/s001250051172

Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., & Colagiuri, S. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26(3), 268–278. https://doi.org/10.1111/j.1464-5491.2009.02666.x

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016a). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016b). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827

Merlin C. Thomas. (2016). Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy, 7(3). https://doi.org/doi:  10.1007/s13300-016-0189-4

Michael Riddell. (2009). Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of Diabetes Science and Technology (Online), 3(4). https://doi.org/doi:  10.1177/193229680900300439

Min, S. H., Yoon, J.-H., Hahn, S., & Cho, Y. M. (2017). Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews, 33(1). https://doi.org/10.1002/dmrr.2818

Minimizing Hypoglycemia in Diabetes: Table 1. (2015). Diabetes Care, 38(8), 1583–1591. https://doi.org/10.2337/dc15-0279

Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015a). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 109(2), 378–388. https://doi.org/10.1016/j.diabres.2015.05.025

Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015b). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 109(2), 378–388. https://doi.org/10.1016/j.diabres.2015.05.025

Moreno-Castilla, C., Mauricio, D., & Hernandez, M. (2016). Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports, 16(4). https://doi.org/10.1007/s11892-016-0717-7

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29(8), 1963–1972. https://doi.org/10.2337/dc06-9912

Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism, 18(3), 203–216. https://doi.org/10.1111/dom.12591

Nauck, M. A., & Meier, J. J. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology, 4(6), 525–536. https://doi.org/10.1016/S2213-8587(15)00482-9

Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., & Stein, P. P. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 9(2), 194–205. https://doi.org/10.1111/j.1463-1326.2006.00704.x

Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 37(8), 2149–2158. https://doi.org/10.2337/dc13-2761

Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine, 356(24), 2457–2471. https://doi.org/10.1056/NEJMoa072761

Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015). Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes, 64(3), 673–686. https://doi.org/10.2337/db14-0694

Paul Craddy. (2014). Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy, 5(1). https://doi.org/doi:  10.1007/s13300-014-0061-3

Persaud, S. J., & Jones, P. M. (2016). A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine, 375(11), 1090–1092. https://doi.org/10.1056/NEJMcibr1607950

Postnatal testing following gestational diabetes- ClinicalKey. (n.d.). https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. (4 C.E.). https://www.youtube.com/watch?v=AhhWTmEFuag

Qin, L., Knol, M. J., Corpeleijn, E., & Stolk, R. P. (2010). Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology, 25(1), 5–12. https://doi.org/10.1007/s10654-009-9395-y

Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., & Garber, A. (2005). Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care, 28(2), 260–265. https://doi.org/10.2337/diacare.28.2.260

Resources and tools. (n.d.-a). http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html

Resources and tools. (n.d.-b). http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html

Resources and tools. (n.d.-c). http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html

Richard I. G. Holt, ,  Clive Cockram, ,  Allan Flyvbjerg, , and  Barry J. Goldstein. (2016). Textbook of Diabetes. John Wiley. https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056

Richter, B., & Neises, G. (1996). ‘Human’ insulin versus animal insulin in people with diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD003816.pub2

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care, 36(9), 2489–2496. https://doi.org/10.2337/dc12-2454

Rinki Murphy. (2015). Monogenic diabetes and pregnancy. Obstetric Medicine, 8(3). https://doi.org/doi:  10.1177/1753495X15590713

Rizos, C. V., Kei, A., & Elisaf, M. S. (2016). The current role of thiazolidinediones in diabetes management. Archives of Toxicology, 90(8), 1861–1881. https://doi.org/10.1007/s00204-016-1737-4

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51(3), 408–416. https://doi.org/10.1007/s00125-007-0911-x

Rosenstock, J., Raccah, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013). Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care, 36(10), 2945–2951. https://doi.org/10.2337/dc12-2709

Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015). Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice, 69(5), 531–549. https://doi.org/10.1111/ijcp.12572

Ryder, B., McKnight, J., Blann, A., Dhatariya, K., Gregory, R., Robinson, T., Rowles, S., Sharp, P., Winocour, P. H., & Walton, C. (2013). ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes, 30(9), 388–391. https://doi.org/10.1002/pdi.1816

S M Attard. (2015). Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes, 5(6). https://doi.org/doi:  10.1038/nutd.2015.16

Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com. (n.d.). http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level

Sallis, J. F., Bull, F., Guthold, R., Heath, G. W., Inoue, S., Kelly, P., Oyeyemi, A. L., Perez, L. G., Richards, J., & Hallal, P. C. (2016). Progress in physical activity over the Olympic quadrennium. The Lancet, 388(10051), 1325–1336. https://doi.org/10.1016/S0140-6736(16)30581-5

Samuel, V. T., & Shulman, G. I. (2012). Intergrating Mechanisms  for Insulin Resistance: Common Threads and Missing Links. Cell, 148(5), 852–871. https://doi.org/10.1016/j.cell.2012.02.017

Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine, 376(7), 641–651. https://doi.org/10.1056/NEJMoa1600869

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012a). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine, 366(17), 1567–1576. https://doi.org/10.1056/NEJMoa1200225

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012b). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine, 366(17), 1567–1576. https://doi.org/10.1056/NEJMoa1200225

Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016). The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care, 39(2), 179–186. https://doi.org/10.2337/dc15-1585

Simmons, R. K., Borch-Johnsen, K., Lauritzen, T., Rutten, G. E., Sandbæk, A., van den Donk, M., Black, J. A., Tao, L., Wilson, E. C., Davies, M. J., Khunti, K., Sharp, S. J., Wareham, N. J., & Griffin, S. J. (2016). A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technology Assessment, 20(64), 1–86. https://doi.org/10.3310/hta20640

Sivasubramaniyam, S., Amiel, S. A., & Choudhary, P. (2017). Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine, 34(10), 1456–1460. https://doi.org/10.1111/dme.13438

Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., Sullivan, M., & Wedel, H. (2004). Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine, 351(26), 2683–2693. https://doi.org/10.1056/NEJMoa035622

Srinivasan, B. T., & Davies, M. (2014). Glycaemic management of type 2 diabetes. Medicine, 42(12), 711–717. https://doi.org/10.1016/j.mpmed.2014.09.011

Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008). Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal, 84(996), 524–531. https://doi.org/10.1136/pgmj.2008.067918

Srinivasan, P., Huang, G. C., Amiel, S. A., & Heaton, N. D. (2007). Islet cell transplantation. Postgraduate Medical Journal, 83(978), 224–229. https://doi.org/10.1136/pgmj.2006.053447

Standards of Medical Care in Diabetes--2015: Summary of Revisions. (2015). Diabetes Care, 38(Supplement_1), S4–S4. https://doi.org/10.2337/dc15-S003

Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016). Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care, 39(5), 808–815. https://doi.org/10.2337/dc15-1942

Steven, S., & Taylor, R. (2015). Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine, 32(9), 1149–1155. https://doi.org/10.1111/dme.12722

Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., & Murphy, H. R. (2016). Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine, 375(7), 644–654. https://doi.org/10.1056/NEJMoa1602494

Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (1996). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD006383.pub2

Tanner, M. (2016). Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine, 165(4). https://doi.org/10.7326/ACPJC-2016-165-4-020

Tao, L., Wilson, E. C. F., Wareham, N. J., Sandbaek, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., & Simmons, R. K. (2015). Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine, 32(7), 907–919. https://doi.org/10.1111/dme.12711

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/ng28

Umpierre, D. (2011). Physical Activity Advice Only or Structured Exercise Training and Association With HbA                              Levels in Type 2 Diabetes. JAMA, 305(17). https://doi.org/10.1001/jama.2011.576

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. (n.d.). http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview

Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine, 34(9), 1205–1211. https://doi.org/10.1111/dme.13379

Vloemans, A. F., van Beers, C. A. J., de Wit, M., Cleijne, W., Rondags, S. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Serné, E. H., & Snoek, F. J. (2017). Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine, 34(10), 1470–1476. https://doi.org/10.1111/dme.13429

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 375(4), 323–334. https://doi.org/10.1056/NEJMoa1515920

WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. (n.d.). http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/

Yeh, J. S., Kushner, R. F., & Schiff, G. D. (2016). Obesity and Management of Weight Loss. New England Journal of Medicine, 375(12), 1187–1189. https://doi.org/10.1056/NEJMclde1515935

Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., Hänninen, J., Levänen, H., Lahdenperä, S., Lehtonen, R., & Ryysy, L. (2006). Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia, 49(3), 442–451. https://doi.org/10.1007/s00125-005-0132-0

Young, L. A., & Buse, J. B. (2014). GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet, 384(9961), 2180–2181. https://doi.org/10.1016/S0140-6736(14)61409-4

Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2017). Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care, 40(2), 287.1-287. https://doi.org/10.2337/dc17-er02

Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016). Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal, 92(1084), 63–69. https://doi.org/10.1136/postgradmedj-2015-133281

Zinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., & Mathieu, C. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet, 377(9769), 924–931. https://doi.org/10.1016/S0140-6736(10)62305-7